Cargando…
Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers
Checkpoint inhibitors represent the first therapeutic class to replace chemotherapy lines for the treatment of metastatic non-small cell lung cancer (NSCLC), due to improved overall survival and tolerability. Nivolumab, a fully human anti-programmed cell death-1 immunoglobulin G4 monoclonal antibody...
Autores principales: | Săftescu, Sorin, Negru, Șerban, Volovăț, Simona, Popovici, Dorel, Chercota, Vlad, Stanca, Simona, Feier, Horea, Malita, Daniel, Dragomir, Radu, Volovăț, Constantin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082661/ https://www.ncbi.nlm.nih.gov/pubmed/33936262 http://dx.doi.org/10.3892/etm.2021.10037 |
Ejemplares similares
-
Determining factors of renal dysfunction during cisplatin chemotherapy
por: Săftescu, Sorin, et al.
Publicado: (2021) -
Role of combining neutrophil-to-lymphocyte ratio and pretreatment body mass index in predicting progression-free survival in patients with non-small cell lung cancer treated with nivolumab
por: Dragomir, Radu, et al.
Publicado: (2021) -
Anthropometry in the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020) -
Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020) -
Comparative hematological profiles for dose-dense vs. regular anthracycline-based neoadjuvant chemotherapy in non-metastatic breast cancer
por: Popovici, Dorel, et al.
Publicado: (2021)